SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 3, 2003 |
|
Savient Pharmaceuticals, Inc. |
(Exact name of issuer as specified in its charter) |
Delaware | | 0-15313 | | 13-3033811 |
(State or Other Jurisdiction | | (Commission File Number) | | (IRS Employer |
| | of Incorporation) | | Identification No.) |
One Tower Center, 14th Floor
East Brunswick, New Jersey | | 08816 |
(Address of Principal Executive Offices) | | (Zip Code) |
| | |
Registrant’s telephone number, including area code: (732) 418-9300 |
| | |
None. |
(Former Name or Former Address, if Changed Since Last Report.) |
ITEM 5. | | OTHER EVENTS AND REQUIRED FD DISCLOSURE. |
|
Attached as Exhibit 99.1 hereto is a press release issued by Savient Pharmaceuticals, Inc. (the “Company”) on October 3, 2003 announcing that it is in preliminary acquisition discussions with Teva Pharmaceutical Industries Limited. |
|
ITEM 7. | | FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS. |
|
(c) | | Exhibits. |
|
| | 99.1 | | Press release issued by the Company on October 3, 2003. |
| | | | | | |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
| SAVIENT PHARMACEUTICALS, INC. |
| (Registrant) |
| | |
| By: | /s/ Whitney K. Stearns, Jr. |
| | Whitney K. Stearns, Jr. |
| | Senior Vice President—Chief Financial Officer and Treasurer |
| | |
Dated: October 3, 2003
2
